发明授权
- 专利标题: Oligomeric compounds for the modulation of Bcl-2
- 专利标题(中): 用于调节Bcl-2的低聚物
-
申请号: US11021729申请日: 2004-12-23
-
公开(公告)号: US07622453B2公开(公告)日: 2009-11-24
- 发明人: Miriam Frieden , Jens B. Hansen , Henrik Orum , Majken Westergaard , Charlotte A. Thrue
- 申请人: Miriam Frieden , Jens B. Hansen , Henrik Orum , Majken Westergaard , Charlotte A. Thrue
- 申请人地址: unknown Horsholm
- 专利权人: Santaris Pharma A/S
- 当前专利权人: Santaris Pharma A/S
- 当前专利权人地址: unknown Horsholm
- 代理机构: Fish & Richardson P.C.
- 优先权: DK200301929 20031223; DK200400517 20040331; DK200401069 20040707; DK200401629 20041022
- 主分类号: A01N61/00
- IPC分类号: A01N61/00 ; A01N43/04 ; C12Q1/68 ; C07H21/02 ; C07H21/04
摘要:
The present invention provides improved oligomeric compound, in particular oligonucleotide compounds, and methods for modulating the expression of the Bcl-2 gene in humans. In particular, this invention relates to oligomeric compounds of 10-30 nucleobases in length which comprise a target binding domain that is specifically hybridizable to a region ranging from base position No. 1459 (5′) to No. 1476 (3′) of the human Bcl-2 mRNA, said target binding domain having the formula: 5′-[(DNA/RNA)0-1-(LNA/LNA*)2-7-(DNA/RNA/LNA*)4-14-(LNA/LNA*)2-7-(DNA/RNA)0-1]-3′ and said target binding domain comprising at least two LNA nucleotides or LNA analogue nucleotides linked by a phosphorothioate group (—O—P(O,S)—O—). In particular the oligo is predominantly or fully thiolated. The invention also provides the use of such oligomers or conjugates or chimera for the treatment of various diseases associated with the expression of the Bcl-2 gene, such as cancer.
公开/授权文献
- US20050203042A1 Oligomeric compounds for the modulation of Bcl-2 公开/授权日:2005-09-15